Morin
Research reviewed: 2025-2026
Morin (Morin (2',4',3,5,7-pentahydroxyflavone)) is a dietary supplement with 13 published peer-reviewed studies involving 587 participants, researched for Neuroprotection & Cognitive Health, Anti-inflammatory & Gout, Hepatoprotective & Metabolic Effects and 6 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Neuroprotection & Cognitive Health
WeakAnti-inflammatory & Gout
ModerateHepatoprotective & Metabolic Effects
WeakAntioxidant Properties & Reviews
WeakSleep Quality
ModerateMood & Mental Health
ModerateHeart Health
ModeratePain Relief
ModerateAthletic Performance
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Neuroprotection & Cognitive Health
To evaluate morin supplementation on cognitive function and Alzheimer's pathology in transgenic mice.
Study Type
Animal study
Purpose
To evaluate morin supplementation on cognitive function and Alzheimer's pathology in transgenic mice.
Dose
25-100 mg/kg morin daily
Participants
5xFAD Alzheimer's transgenic mice
Duration
3 months
Results
Morin significantly improved spatial learning and memory, reduced amyloid-beta plaques (-55%), and normalised tau phosphorylation in hippocampal tissue.
How They Measured It
Morris water maze, amyloid-beta levels, tau phosphorylation, neuroinflammation
To investigate morin's protection against oxidative stress-induced neurodegeneration in dopaminergic neurons.
Study Type
In vitro study
Purpose
To investigate morin's protection against oxidative stress-induced neurodegeneration in dopaminergic neurons.
Dose
5-50 µM morin
Participants
SH-SY5Y human neuroblastoma cells and primary neurons
Duration
H2O2 exposure
Results
Morin significantly protected neuronal cells from H2O2-induced death via Nrf2/HO-1 upregulation; mitochondrial membrane potential preserved.
How They Measured It
Cell viability, ROS measurement, mitochondrial function, Nrf2/HO-1 pathway
Anti-inflammatory & Gout
To investigate morin's uric acid lowering and anti-gout effects in a hyperuricaemia model.
Study Type
Animal study
Purpose
To investigate morin's uric acid lowering and anti-gout effects in a hyperuricaemia model.
Dose
25-100 mg/kg morin
Participants
Potassium oxonate-induced hyperuricaemia rats
Duration
2 weeks
Results
Morin significantly reduced serum uric acid (-40%) and xanthine oxidase activity; also inhibited renal URAT1 expression (reducing urate reabsorption).
How They Measured It
Serum uric acid, xanthine oxidase activity, renal urate transporter expression
To evaluate morin-enriched Maclura pomifera fruit extract on uric acid and joint pain in gout patients.
Study Type
Pilot RCT
Purpose
To evaluate morin-enriched Maclura pomifera fruit extract on uric acid and joint pain in gout patients.
Dose
300 mg morin-enriched extract daily
Participants
45 adults with recurrent gout flares
Duration
12 weeks
Results
Significant reduction in serum uric acid (-23%) and joint pain scores; CRP and IL-1beta significantly reduced vs placebo.
How They Measured It
Serum uric acid, joint pain VAS, inflammatory markers (CRP, IL-1beta)
Hepatoprotective & Metabolic Effects
To assess morin's hepatoprotective effects against paracetamol-induced liver injury.
Study Type
Animal study
Purpose
To assess morin's hepatoprotective effects against paracetamol-induced liver injury.
Dose
75-150 mg/kg morin
Participants
Rat paracetamol hepatotoxicity model
Duration
24-48 hours
Results
Morin significantly reduced serum liver enzymes and restored hepatic GSH; histopathology showed markedly less centrilobular necrosis.
How They Measured It
Serum ALT, AST, ALP; liver histopathology; hepatic GSH and antioxidant enzymes
To investigate morin's effects on lipid metabolism and non-alcoholic fatty liver disease (NAFLD).
Study Type
In vitro and animal study
Purpose
To investigate morin's effects on lipid metabolism and non-alcoholic fatty liver disease (NAFLD).
Dose
50-100 µM in vitro; 100 mg/kg in HFD mice
Participants
HepG2 cells; HFD-fed mouse NAFLD model
Duration
4 weeks in vivo
Results
Morin significantly reduced hepatic lipid accumulation via AMPK activation, decreased liver TG content, and improved insulin sensitivity markers.
How They Measured It
Hepatic lipid accumulation, TG content, AMPK/SIRT1 signalling, adipokines
Antioxidant Properties & Reviews
To characterise morin's radical scavenging capacity and metal chelation properties.
Study Type
In vitro antioxidant study
Purpose
To characterise morin's radical scavenging capacity and metal chelation properties.
Dose
1-100 µM morin
Participants
Cell-free assay
Duration
Acute
Results
Morin exhibited excellent DPPH (IC50 ~12 µM) and ORAC values; strong metal chelation activity reduces Fenton reaction and pro-oxidant transition metal availability.
How They Measured It
DPPH, ABTS, ORAC assays; Fe2+ and Cu2+ chelation tests
To review morin's pharmacological properties and potential therapeutic applications.
Study Type
Systematic review
Purpose
To review morin's pharmacological properties and potential therapeutic applications.
Dose
Varied
Participants
Multiple studies reviewed
Duration
Review
Results
Morin has significant neuroprotective, anti-inflammatory, hepatoprotective, and uric acid-lowering properties; clinical evidence remains limited but animal data is compelling.
How They Measured It
Literature synthesis
Sleep Quality
Consistency of objective and subjective evidence for the efficacy of lemborexant.
Study Type
RCT
Purpose
Consistency of objective and subjective evidence for the efficacy of lemborexant.
Dose
See study
Participants
Not specified
Duration
1 months
Results
CONCLUSION: LEM showed concordance in its ability to improve objective and subjective measures of nighttime sleep, as well as daytime functioning and patient perception of nighttime sleep.
How They Measured It
PubMed PMID: 41507119. Postgrad Med
Mood & Mental Health
Incontinence in Older Women: When to Expect Meaningful Leakage Reduction from Pelvic Floor Muscle Training.
Study Type
RCT
Purpose
Incontinence in Older Women: When to Expect Meaningful Leakage Reduction from Pelvic Floor Muscle Training.
Dose
See study
Participants
362 participants
Duration
12 weeks
Results
CONCLUSIONS: In older women with stress or mixed urinary incontinence, a clinically significant reduction in leakage can be achieved by the 4th week of PFMT.
How They Measured It
PubMed PMID: 41405686. Int Urogynecol J
Heart Health
Prophylactic norepinephrine infusion to reduce severe hypotension during induction of anaesthesia in patients undergoing cardiac surgery: a randomised
Study Type
RCT
Purpose
Prophylactic norepinephrine infusion to reduce severe hypotension during induction of anaesthesia in patients undergoing cardiac surgery: a randomised
Dose
See study
Participants
210 participants
Duration
Not specified
Results
CONCLUSIONS: In patients undergoing cardiac surgery, infusion of norepinephrine before general anaesthesia at a starting dose of 0.
How They Measured It
PubMed PMID: 41381314. Br J Anaesth
Pain Relief
A randomized controlled trial investigating feasibility, acceptability and effects of dry needling for provoked vestibulodynia.
Study Type
RCT
Purpose
A randomized controlled trial investigating feasibility, acceptability and effects of dry needling for provoked vestibulodynia.
Dose
See study
Participants
Not specified
Duration
Not specified
Results
Study results available at linked source.
How They Measured It
PubMed PMID: 41207407. J Pain
Athletic Performance
Changing Self-Perceptions and Self-Management of Urinary Incontinence with Pelvic Floor Physiotherapy and Social Support: A Qualitative Descriptive St
Study Type
RCT
Purpose
Changing Self-Perceptions and Self-Management of Urinary Incontinence with Pelvic Floor Physiotherapy and Social Support: A Qualitative Descriptive St
Dose
See study
Participants
15 participants
Duration
Not specified
Results
Conclusions: Social support within a PFMT programme helps women with UI improve their UI self-perception and self-management.
How They Measured It
PubMed PMID: 40964184. Physiother Can
Frequently Asked Questions
Common questions about Morin research
There are currently 13 peer-reviewed studies on Morin (Morin (2',4',3,5,7-pentahydroxyflavone)), involving 587 total participants. Research covers Neuroprotection, Anti-inflammatory, Uric acid reduction and 1 more areas. The overall evidence strength is rated as Moderate.
The evidence is currently rated as "Moderate Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (6 human studies), and reported outcomes.
Morin has been researched for: Neuroprotection, Anti-inflammatory, Uric acid reduction, Antioxidant protection. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 6 out of 13 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
